Loading...
Doxycycline directly targets PAR1 to suppress tumor progression
Doxycycline have been reported to exert anti-cancer activity and have been assessed as anti-cancer agents in clinical trials. However, the direct targets of doxycycline in cancer cells remain unclear. In this study, we used a chemical proteomics approach to identify the Protease-activated receptor 1...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5370004/ https://ncbi.nlm.nih.gov/pubmed/28187433 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15166 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|